## IN THE UNITED STATES DISTRICT COURT FOR THE DISTICT OF DELAWARE

AMARIN PHARMA, INC., AMARIN : PHARMACEUTICALS IRELAND : LIMITED, MOCHIDA : PHARMACEUTICAL CO., LTD., :

.

Plaintiffs,

•

v. : C.A. No. 20-1630-RGA-JLH

:

HIKMA PHARMACEUTICALS USA INC., HIKMA PHARMACEUTICALS PLC, AND HEALTH NET, LLC

:

Defendants.

### BRIEF IN SUPPORT OF HIKMA'S MOTION FOR ENTRY OF FINAL AND APPEALABLE JUDGMENT UNDER FEDERAL RULE OF CIVIL PROCEDURE 54(b)

#### OF COUNSEL:

Charles B. Klein Claire A. Fundakowski WINSTON & STRAWN LLP 1901 L Street, NW Washington, DC 20036 (202) 282-5000

Eimeric Reig-Plessis WINSTON & STRAWN LLP 101 California Street San Francisco, CA 94111 (415) 591-6808

Alison M. King WINSTON & STRAWN LLP 35 W. Wacker Drive Chicago, IL 60601 (312) 558-5600 HEYMAN ENERIO
GATTUSO & HIRZEL LLP
Dominick T. Gattuso (#3630)
300 Delaware Avenue, Suite 200
Wilmington, DE 19801
(302) 472-7300
dgattuso@hegh.law

Attorneys for Defendants Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals PLC



## **TABLE OF CONTENTS**

		Pa	ge	
I.	INTI	ODUCTION	1	
II.	BACKGROUND2			
	A.	Amarin originally filed its claims against Hikma alone and added factually distinct claims against Health Net after Hikma moved to dismiss.	2	
	B.	The Court dismissed all claims against Hikma but did not dismiss Amarin's separate infringement claims against Health Net	3	
	C.	Hikma has consistently sought entry of a final and appealable judgment to obtain patent certainty, which the other parties have not opposed.	4	
III.	LEG	AL STANDARD	5	
IV.	ARGUMENT7			
	A.	The dismissal of Amarin's claims against Hikma is a final judgment.	7	
	B.	There is no just reason for delaying entry of an appealable judgment		
		1. There is no meaningful overlap between the adjudicated claims against Hikma and the unadjudicated claims against Health Net	8	
		2. Any possibility that the need for review might be mooted by future developments does not warrant delay.	10	
		3. There is no foreseeable possibility that the Federal Circuit will need to consider the same issue a second time.	12	
		4. There is no counterclaim that could result in any set-off	13	
		5. No miscellaneous factors weigh against immediate review	13	
V.	CON	CLUSION	14	



## **TABLE OF AUTHORITIES**

Page(s
Cases
Allis-Chalmers Corp. v. Philadelphia Elec. Co., 521 F.2d 360 (3d Cir. 1975)
Berckeley Inv. Grp., Ltd. v. Colkitt, 455 F.3d 195 (3d Cir. 2006)
Bogosian v. Gulf Oil Corp., 561 F.2d 434 (3d Cir. 1977)
Commissariat à l'Énergie Atomique v. Chi Mei Optoelectronics Corp., 293 F. Supp. 2d 430, 434-35 (D. Del. 2003), vacated on other grounds, 395 F.3d 1315 (Fed. Cir. 2005)
Curtiss-Wright Corp. v. Gen. Elec. Co., 446 U.S. 1 (1980)
ImageCube LLC v. The Boeing Co., No. 04-7587, 2010 WL 331723 (N.D. Ill. Jan. 22, 2010)10
Intell. Ventures I LLC v. Cap. One Fin. Corp., 850 F.3d 1332 (Fed. Cir. 2017)
Interdigital Commc'ns, Inc. v. ZTE Corp., No. 13-009-RGA, 2016 WL 3226011 (D. Del. June 7, 2016)
Keurig, Inc. v. Sturm Foods, Inc., No. 10-841-SLR, 2012 WL 12896333 (D. Del. Nov. 2, 2012), aff'd, 732 F.3d 1370 (Fed. Cir. 2013)
Loral Fairchild Corp. v. Victor Co. of Japan, 931 F. Supp. 1044 (E.D.N.Y. 1996)
Medifast, Inc. v. Minkow, No. 10-0382-CAB (BGS), 2012 WL 13175888 (S.D. Cal. Apr. 13, 2012)12
Polar Electro Oy v. Amer Sports Winter & Outdoor, No. 11-1100-GMS, 2015 WL 13842059 (D. Del. July 17, 2015)10
Storage Tech. Corp. v. Cisco Sys., Inc., 329 F.3d 823 (Fed. Cir. 2003)
Teva Pharms. USA, Inc. v. Novartis Pharms. Corp., 482 F.3d 1330 (Fed. Cir. 2007)



## TABLE OF AUTHORITIES—continued

	Page(s)
Woodard v. Sage Prods., Inc., 818 F.2d 841 (Fed. Cir. 1987)	6
Other Authorities	
Dan Bagatell, "Fed. Circ. Patent Decisions In 2021: An Empirical Review," Law360 (Jan. 6, 2022), available at	
https://www.law360.com/articles/1452355	11
Fed. R. Civ. P. 54(b)	1, 2, 5



### I. INTRODUCTION

Hikma respectfully moves for entry of a final and appealable judgment under Federal Rule of Civil Procedure 54(b). The Court has already dismissed all claims against Hikma (D.I. 97, 98), and the only reason the Court's decision is not immediately appealable is that Amarin's separate claims against another defendant, Health Net, remain pending. Amarin added the claims against Health Net in its first amended complaint (D.I. 17, Counts IV–VI), and those claims are distinct from the now-dismissed claims against Hikma (*id.*, Counts I–III), which Amarin initially brought in its original complaint against Hikma alone (D.I. 1).

Where, as here, "more than one claim" or "multiple parties are involved, the court may direct entry of a final judgment as to one or more, but fewer than all, claims or parties only if the court expressly determines that there is no just reason for delay." Fed. R. Civ. P. 54(b). As shown below, there is "no just reason" to delay entry of final judgment on Amarin's claims against Hikma, which will allow Hikma to achieve patent certainty that would otherwise be delayed for well over a year by the pending litigation against Health Net.

Under the current case schedule, the trial between Amarin and Health Net will not take place until October 30, 2023. D.I. 50 at 14–15, ¶ 20. Even after a verdict, a final judgment on all claims will not be entered until the Court rules on post-trial motions. In the meantime, while Hikma is confident that the decision granting its motion to dismiss is correct, Hikma bears the uncertainty and risk that this decision could one day be reversed—potentially exposing Hikma to damages claims for ongoing sales of its accused generic drug product. That uncertainty frustrates the policy goals of "prompt resolution" and "patent certainty" in pharmaceutical patent disputes, which benefit litigants and consumers alike. *See, e.g., Teva Pharms. USA, Inc. v. Novartis Pharms. Corp.*, 482 F.3d 1330, 1342 (Fed. Cir. 2007) (discussing legislative history of Hatch-Waxman amendments "to obtain patent certainty").



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

